Half-year report · HY
2503.TEDINET S100YV8N
Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.22T | 2026-01-01 → 2026-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.43T | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.14T | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥129.0bn | 2026-01-01 → 2026-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥68.7bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥150.9bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥237.9bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥83.8bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥101.7bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥147.5bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥52.8bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥116.1bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥60.5bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.40T | at 2026-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.49T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.30T | at 2025-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.72T | at 2026-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.90T | at 2025-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.68T | at 2026-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.60T | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.41T | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.53T | at 2024-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.36T | at 2026-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.29T | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.12T | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥168.1bn | at 2026-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥125.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥132.4bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.6bn | at 2024-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥137.3bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥295.4bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥67.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥53.7bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥185.0bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥61.6bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥162.5bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥110.5bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥35.8bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥126.33 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥182.13 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥65.23 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥182.13 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥65.22 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 40.0% | at 2026-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.8% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 34.0% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2026-01-01 → 2026-06-30 | ¥46.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥12.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥33.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥38.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥38.9bn |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥34.2bn |
| Alcoholic Beveragesreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥519.1bn |
| Alcoholic Beveragesreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥517.8bn |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥1.3bn |
| Alcoholic Beveragesreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥62.1bn |
| Health Sciencereportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥131.1bn |
| Health Sciencereportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥128.8bn |
| Health Sciencereportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥2.3bn |
| Health Sciencereportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥10.4bn |
| Non Alcoholic Beveragesreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥296.7bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥294.9bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥1.8bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥31.0bn |
| Pharmaceuticalsreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥263.6bn |
| Pharmaceuticalsreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥263.5bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥139m |
| Pharmaceuticalsreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥60.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥47.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥14.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥32.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥591m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥38.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥38.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥30.0bn |
| Alcoholic Beveragesreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥493.8bn |
| Alcoholic Beveragesreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥492.6bn |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.2bn |
| Alcoholic Beveragesreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥53.2bn |
| Health Sciencereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥129.7bn |
| Health Sciencereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥127.2bn |
| Health Sciencereportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| Health Sciencereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥8.6bn |
| Non Alcoholic Beveragesreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥273.4bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥271.8bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.6bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥29.5bn |
| Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥230.7bn |
| Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥230.5bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥156m |
| Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥33.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 869
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in short term borrowings fin cf IFRS | InterimDuration | 997000000 | JPY |
| Increase decrease in commercial paper fin cf IFRS | Prior1InterimDuration | 107976000000 | JPY |
| Increase decrease in commercial paper fin cf IFRS | InterimDuration | -15995000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1InterimDuration | -20000000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | InterimDuration | -25000000000 | JPY |
| Proceeds from issuance of bonds fin cf IFRS | Prior1InterimDuration | 100000000000 | JPY |
| Proceeds from issuance of bonds fin cf IFRS | InterimDuration | - | JPY |
| Redemption of bonds fin cf IFRS | Prior1InterimDuration | -25000000000 | JPY |
| Redemption of bonds fin cf IFRS | InterimDuration | -40000000000 | JPY |
| Repayments of lease obligations fin cf IFRS | Prior1InterimDuration | -9506000000 | JPY |
| Repayments of lease obligations fin cf IFRS | InterimDuration | -10037000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | Prior1InterimDuration | -9000000 | JPY |
| Payments for purchase of treasury shares fin cf IFRS | InterimDuration | -34554000000 | JPY |
| Purchase of treasury stock of subsidiaries in consolidation fin cf IFRS | Prior1InterimDuration | -4000000 | JPY |
| Purchase of treasury stock of subsidiaries in consolidation fin cf IFRS | InterimDuration | -6000000 | JPY |
| Dividends paid fin cf IFRS | Prior1InterimDuration | -28755000000 | JPY |
| Dividends paid fin cf IFRS | InterimDuration | -29975000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | Prior1InterimDuration | -6988000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | InterimDuration | -7846000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1InterimDuration | -81605000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | InterimDuration | - | JPY |
| Other fin cf IFRS | Prior1InterimDuration | -385000000 | JPY |
| Other fin cf IFRS | InterimDuration | -57000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1InterimDuration | 35825000000 | JPY |
| Net cash provided by used in financing activities IFRS | InterimDuration | -162473000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1InterimDuration | -3926000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | InterimDuration | 14244000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1InterimDuration | 37596000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | InterimDuration | 42783000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 118617000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 125292000000 | JPY |
| Effect of changes in accounting policies cce IFRS | Prior2YearInstant | -10731000000 | JPY |
| Effect of changes in accounting policies cce IFRS | Prior1YearInstant | - | JPY |
| Restated cash and cash equivalents at beginning of period cce IFRS | Prior2YearInstant | 107886000000 | JPY |
| Restated cash and cash equivalents at beginning of period cce IFRS | Prior1YearInstant | 125292000000 | JPY |
| Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRS | Prior1InterimDuration | -13074000000 | JPY |
| Net increase decrease in cash and cash equivalents resulting from transfer to assets held for sale IFRS | InterimDuration | - | JPY |
| Cash and cash equivalents IFRS | Prior1InterimInstant | 132408000000 | JPY |
| Cash and cash equivalents IFRS | InterimInstant | 168075000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 492628000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 271805000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 230498000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 127247000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 14132000000 | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration_ReconcilingItemsMember | - | JPY |
| Revenue from external customers IFRS | Prior1InterimDuration | 1136309000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 1159000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 1598000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 156000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 2489000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |